Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.
about
Functional Status Assessment of COPD Based on Ability to Perform Daily Living Activities: A Systematic Review of Paper and Pencil InstrumentsBiomarker validation and testingAssessing the clinical utility of cancer genomic and proteomic data across tumor types.HER2/neu Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study.Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology.Tumor markers in clinical practice: General principles and guidelines.Contribution of biomarkers to personalized medicine.Combining biomarkers to optimize patient treatment recommendations.Use of archived specimens in evaluation of prognostic and predictive biomarkersp53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewTargeting a common collaborator in cancer development.Publication of tumor marker research results: the necessity for complete and transparent reporting.EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancerThe gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome.Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkersFuture directions for monitoring treatment responses in breast cancer.Statistical and practical considerations for clinical evaluation of predictive biomarkers.Molecular markers of breast axillary lymph node metastasis.Breaking a vicious cycle.DNA methylation markers for early detection of women's cancer: promise and challenges.CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.The pathway to clinical use of a cancer biomarker.The reproducibility of biomedical research: Sleepers awake!Predictive tests for individualization of pharmacological cancer treatment.BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.Case-only approach to identifying markers predicting treatment effects on the relative risk scale.The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size.Evaluation of biomarkers for treatment selection using individual participant data from multiple clinical trials.
P2860
Q26780344-172E0026-C0FA-4857-A17A-460A4FB4DC26Q26863672-0A29D260-1A1F-4462-8DC7-350D00B883AAQ30487077-4E50F778-3A92-452F-9176-F6A08878805BQ33741544-3DF9D420-E62F-4074-BFDB-96253DF9D3FCQ33775506-A1922B44-3CDE-41CF-B978-E1AC3E694A6CQ33985481-3A1DEF0B-4C2E-4894-8F12-641057823A59Q34423459-094BB3A2-09C7-41C7-9E88-8F0EF82DA79CQ34588910-5D009AD7-0D4C-4449-BE7D-E2D5D558C504Q35007222-5892FF7D-835D-4A9D-8094-84F373064A10Q35146274-1316524A-1541-48E9-BD8E-539C82B7B2D4Q35904441-108CB5FB-E443-4910-B25B-29D681B54D18Q36184185-5F5F0499-F5F6-43F0-9161-C434C90DE8D1Q36417739-9148BD52-B749-409D-8002-B2734F292B30Q37225289-67D0E30F-335D-4D69-B983-3D1330ABC29EQ37254126-B0E4ED20-1263-4E75-B985-9901BF0368D3Q37326197-F15B67FC-77FB-48DA-8781-5703935DC8D6Q37435201-65B4E5E6-AAA9-4EA9-A8A2-48C8AC60BF56Q37463622-2E91F6EC-7FE1-4F09-B965-05E68A6ACE55Q37542255-E712972D-173D-4178-8682-46F8731165E0Q38125603-D46E7EAD-6708-41A3-BECF-0C75D3986EA5Q38238828-BE73A90E-EBC0-4BDC-923B-2B88478F41D9Q38668766-AD41A7DA-675F-4CF8-86FA-909D14753980Q38895171-BA0E709D-E0B7-4166-8732-2A4EF5AEF5F2Q39023051-F53A4E3A-4779-4E2F-AF16-E230C691121AQ40109282-81206E20-FB20-4BE8-86FC-FC06FAAFA54AQ40870110-C68B785E-80C1-4CDF-8E86-ED4CEBB1530AQ41993145-19F7DAF4-A8F8-4275-AFDF-5222220BF36AQ47110861-FC1A93D8-C527-47A1-90F5-DB258B2B56BFQ47222967-E1643FF5-6890-4E5F-A6E3-90362A04B8C0Q49996939-6067BAB7-65D4-4F13-AD67-1A5023CEDDD3
P2860
Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Uses and abuses of tumor marke ...... and metastatic breast cancer.
@ast
Uses and abuses of tumor marke ...... and metastatic breast cancer.
@en
type
label
Uses and abuses of tumor marke ...... and metastatic breast cancer.
@ast
Uses and abuses of tumor marke ...... and metastatic breast cancer.
@en
prefLabel
Uses and abuses of tumor marke ...... and metastatic breast cancer.
@ast
Uses and abuses of tumor marke ...... and metastatic breast cancer.
@en
P1433
P1476
Uses and abuses of tumor marke ...... and metastatic breast cancer.
@en
P2093
Daniel F Hayes
N Lynn Henry
P304
P356
10.1634/THEONCOLOGIST.11-6-541
P577
2006-06-01T00:00:00Z